Relora survey finds 91 percent positive response
SALINAS, Calif. Next Pharmaceuticals on Tuesday released the results of an open label study on Relora. The study was conducted at The LaValle Metabolic Institute in Cincinnati, Ohio among 1,291 participants who suffered from stress, sleeplessness and/or stress-related eating.
According to the survey, 91 percent of the subjects reported Relora helped them relax, 90 percent reported Relora helped them have a restful sleep and 86 percent reported Relora helped prevent stress-related eating.
“This study demonstrates that Relora can be a successful adjunct for individuals who experience stress and anxiety, or who turn to food when dealing with tension,” stated Charles Kosmont, chief executive officer of Next Pharmaceuticals. “There are many methods to managing stress, and Dr. LaValle’s clinical study supports the fact that Relora is a natural, safe and effective approach with no toxic side effects.”
Relora consists of a patented blend of Magnolia bark extract and a proprietary blend of Phellodendron bark extract developed by Next Pharmaceuticals for the dietary supplement and functional food and beverage industries. Dr. James LaValle, author of Cracking the Metabolic Code, was the principal investigator of the study.
The subjects rated the efficacy of Relora on a 5-point scale. The product was considered effective for stress, restful sleep and stress-related eating if the subject rated the product 3 or higher. This study was developed as an open label, single center, clinical trial involving a minimum of 500 subjects with mild to moderate stress. Dr. LaValle enrolled both male and female subjects in the study as appropriate from patients at his clinic.
Bayer announces deal to buy Citracal
MORRISTOWN, N.J. Bayer HealthCare on Thursday announced an agreement with Mission Pharmacal Company to acquire its global Citracal line of over-the-counter calcium supplements.
The companies have not disclosed the financial terms of the transaction, which is expected to close during the fourth quarter of 2007 subject to regulatory approvals.
“Our consumer health businesses are a key component of Bayer HealthCare and we will continue to invest in this area in order to maintain a diversified portfolio,” stated Arthur Higgins, chairman of Bayer HealthCare. “This acquisition further affirms our strategy and commitment to grow our consumer health segments and will help to solidify our number two position in the global OTC market.”
“The Citracal brand offers very attractive growth potential both in the critically important U.S. market and for our nutritionals portfolio, which is a key growth driver for us now and in the future,” stated Gary Balkema, president of Bayer HealthCare’s Consumer Care Division.
Citracal is primarily sold in North America and saw net sales of $47 million for fiscal year 2007.
This acquisition will increase Bayer Consumer Care’s market presence in the United States, which includes leading dietary supplement brands like One-A-Day.
Corgenix announces FDA approval for test to measure effectiveness of Aspirin
DENVER Corgenix Medical Corporation on Monday announced the recent introduction of its AspirinWorks Test Kit to doctors following approval from the Food and Drug Administration.
“We are pleased that AspirinWorks testing is now offered nationally through the LabCorp network of laboratories, making the test available to virtually every physician in the U.S.,” stated Corgenix’ clinical affairs director Gordon Ens.
The new test, which was launched nationwide in June following FDA 510(k) clearance, measures aspirin effectiveness on platelets through direct measurement of thromboxane production (aspirin’s target). The stickier the blood platelets, the less impact the aspirin is having. This information allows physicians to individualize a patient’s therapy.
“In the past few months, we have experienced a rapid increase in public interest for the AspirinWorks test,” stated Douglass Simpson, Corgenix’ president and chief executive officer. “There is growing acceptance among physicians to test for aspirin effectiveness, and we expect that by the end of 2007 a significant number of the most important clinical labs will be routinely running this test.”